EP0062

DRUG2 trials

Sponsors

Ellipses Pharma Limited, Ellipses Pharma

Conditions

Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerHormone Receptor-positive Breast CancerMetastatic Breast Cancer

Phase 1

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

RecruitingNCT05573126

Ellipses PharmaHormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

Start: 2023-01-11End: 2028-02-01Target: 95Updated: 2026-03-20

A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as monotherapy and in combination in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

RecruitingCTIS2023-507738-26-00

Ellipses Pharma LimitedBreast Cancer

Start: 2024-03-20Target: 25Updated: 2025-10-02

Related Papers

Abstract P2-10-18: A study to evaluate the safety and efficacy of vosilasarm (EP0062), an oral SARM, as monotherapy and in combination with standard of care regimens in patients with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer

Clinical Cancer Research2025-06-13

Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2- breast cancer.

Journal of Clinical Oncology2025-05-28